Celgene Corporation (CELG)
(Delayed Data from NSDQ)
$96.88 USD
+1.67 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $96.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.88 USD
+1.67 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $96.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Novartis Reports Updated Results from Kymriah's JULIET Study
by Zacks Equity Research
Novartis (NVS) announced updated results from the JULIET study, which show Kymriah sustained complete responses at six months in adults with relapsed or refractory diffuse large B-cell lymphoma.
Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today
by Ryan McQueeney
Shares of Bluebird Bio (BLUE) were up nearly 20% in early morning trading Monday as investors responded to the company's announcement that its CAR-T candidate, bb2121, produced encouraging results in patients with a deadly blood cancer.
The Zacks Analyst Blog Highlights: Bank of America, Celgene, Goldman Sachs, L Brands and Quest Diagnostics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bank of America, Celgene, Goldman Sachs, L Brands and Quest Diagnostics
Gilead Sciences to Acquire Cell Design Labs for $567 Million
by Zacks Equity Research
Gilead Sciences, (GILD) and its subsidiary Kite announced that they have inked an agreement to acquire Cell Design Labs, for an upfront payment of $175 million.
Sanofi Begins Combo Studies on Multiple Myeloma Candidate
by Zacks Equity Research
Sanofi (SNY) starts two new phase III studies evaluating isatuximab in combination with other cancer medicines for the treatment of multiple myeloma, a rare blood cancer.
Why Is Celgene (CELG) Up 3.4% Since the Last Earnings Report?
by Zacks Equity Research
Celgene (CELG) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CAR-T Therapy Space 2017 Progress Report
by Zacks Equity Research
Given the vast potential of the CAR T therapy space and two recent approvals, biotech companies are leaving no stone unturned to develop their pipeline candidates.
J&J Seeks Darzalex's Label Expansion in First-Line Setting
by Zacks Equity Research
Johnson & Johnson (JNJ) has submitted regulatory applications in the United States and EU for label expansion of Darzalex as first-line therapy for multiple myeloma.
Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks
by Arpita Dutt
FDA approval for Ultragenyx's (RARE) rare disease drug and pipeline setbacks faced by Acorda and Cytokinetics were the main news this week in the biotech sector.
Agios Posts New Data on Glioma Candidate from Dose Expansion
by Zacks Equity Research
Agios (AGIO) presents new data from the dose expansion part of a phase I study, evaluating ivosidenib as a single agent for treating IDH1m glioma, at the Society for Neuro-Oncology in San Francisco.
Celgene CAR-T Therapy Gets Breakthrough Therapy Designation
by Zacks Equity Research
FDA grants Breakthrough Therapy Designation to Celgene's (CELG) chimeric antigen receptor T-cell (CAR-T) therapy candidate, bb2121.
The Zacks Analyst Blog Highlights: Facebook, Celgene, BlackRock, Danaher and BP
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Celgene, BlackRock, Danaher and BP
Top Stock Reports for Facebook, Celgene & BlackRock
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Celgene (CELG) and BlackRock (BLK).
Corcept (CORT) Q3 Earnings Miss Estimates, Guidance Raised
by Zacks Equity Research
Corcept Therapeutics' (CORT) earnings miss but sales beat expectations in the third quarter of 2017. The company remains focused on advancing its cortisol modulation platform.
Agios (AGIO) Q3 Loss Narrower than Expected, Revenues Up Y/Y
by Zacks Equity Research
Agios (AGIO) reports narrower-than-expected loss with revenues marginally beating estimates. The top line also improves year over year, thanks to reimbursement received from Celgene.
Biotech Stock Roundup: Celgene, Amgen, Gilead Hit by Q3 Results, Vertex Beats on All Fronts
by Arpita Dutt
It was all about earnings this week with major biotech companies like Gilead (GILD), Celgene and Amgen reporting third quarter results.
Agios Pharmaceuticals (AGIO) Q3 Earnings: What's in Store?
by Zacks Equity Research
Agios' (AGIO) only marketed drug Idhifa that looks effective to cure patients with relapsed or refractory acute myeloid leukemia might drive the company's earnings in Q3.
Busiest Day Of The Q3 Earnings Season
by Zacks Equity Research
Busiest Day Of The Q3 Earnings Season
Celgene (CELG) Tops Q3 Earnings, Sales Miss, Updates View
by Zacks Equity Research
Celgene (CELG) beats third-quarter 2017 earnings estimates on the back of robust Revlimid performance.
Tall Data in Short Time
by Mark Vickery
Plenty of S&P 500 companies have already reported earnings before the opening bell today, and if that's not enough, we've also got tons of economic data and newsworthy financial information to get to.
Celgene (CELG) Beats on Q3 Earnings, Misses Sales
by Ekta Bagri
Celgene (CELG) beat on third-quarter 2017 earnings but revenues missed expectations.
Is Celgene (CELG) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Celgene Corporation (CELG) is expected to beat estimates once again on the back of strong performance of key drug Revlimid.
Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?
by Zacks Equity Research
Bristol-Myers' (BMY) Opdivo is expected to generate increased revenues following its label expansion in the third quarter of 2017. Approval of Orencia in psoriatic arthritis is also a positive.
Gilead Drug Approval Fuels Interest in CAR-T Space: 3 Stocks to Consider
by Arpita Dutt
Will the FDA approval of Novartis and Gilead's (GILD) CAR-T cell therapies fuel more partnership deals and acquisitions in this space?
Gilead (GILD) CAR-T Therapy Yescarta Clinches FDA Approval
by Zacks Equity Research
Gilead (GILD) wins the FDA approval for its CAR-T therapy, Yescarta, for treating refractory aggressive non-Hodgkin lymphoma.